Pliant Therapeutics
PLRX
76 hedge funds and large institutions have $1.21B invested in Pliant Therapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 4 closing their positions.
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
86% more capital invested
Capital invested by funds: $648M → $1.21B (+$560M)
25% more funds holding
Funds holding: 61 → 76 (+15)
5.58% more ownership
Funds ownership: 80.37% → 85.95% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.95M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.47M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.9M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$5.88M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.74M |
| 4 |
CA
CHI Advisors
New York
|
-$974K |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$341K |
PLRX Hedge Fund Activity: Q1 2021 in Review
76 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q1 2021, worth a combined $1.21B — up 86% from $648M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PLRX positions and 4 closed out — a net gain of 15 holders — while 29 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $26.6M. The largest seller was Eventide Asset Management, cutting an estimated $11.9M.
- 76 institutional investors held Pliant Therapeutics (PLRX) as of Q1 2021, up from 61 in Q4 2020.
- Funds reported $1.21B of Pliant Therapeutics stock for Q1 2021, up 86% quarter-over-quarter.
- 19 funds opened new Pliant Therapeutics positions in Q1 2021 and 4 closed out, a net change of +15 holders.
- The largest Pliant Therapeutics buyer in Q1 2021 was BlackRock, an estimated $26.6M added.
- The largest Pliant Therapeutics seller in Q1 2021 was Eventide Asset Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2021.